A



B

Treatment	SUCRA	PrBest	Mean rank
Met+DPP4i	87.7	40.5	2.6
DPP4i+TZD	82.2	26.8	3.3
DPP4i+SGLT2i	76.4	11.3	4.1
Met+GLP-1RA	75.7	9.4	4.2
Met+SGLT2i	69.8	5.4	4.9
SGLT2i	60.3	1.9	6.2
Met	49.5	0.0	7.6
Met+SU	47.0	4.2	7.9
TZD	44.3	0.2	8.2
Met+TZD	33.5	0.1	9.7
SU	30.5	0.1	10.0
GLP-1RA	25.8	0.1	10.6
DPP4i	16.7	0.0	11.8
Placebo	0.4	0.0	13.9

Supplementary Fig. 3. Network geometry (A), and the results of rank test (B) for efficacy of antidiabetic treatments on fasting blood glucose after 6 months. (A) Each circle represents an antidiabetic treatment that was included in the analysis, with the size of the circle proportional to the number of trials involving the treatment. The width of each connecting line is proportional to the number of subjects who participated in each pair of trials. The global test for inconsistency yielded a *P* value of 0.0545, which suggests that there may be inconsistencies present in the network of treatments. (B) The table presents the results of the network rank test (surface under the cumulative ranking curve [SUCRA], probability of being the best [PrBest], mean rank) for different antidiabetic treatments, ordered by mean rank. (C) Network (upper right side) and pairwise (lower left side) meta-analytic results are depicted for fasting blood glucose (mg/dL) reduction efficacy of antidiabetic treatments after 6 months. The outcome of meta-analysis is expressed as effect size with 95% credible intervals in the case of network meta-analysis and 95% confidence intervals in the case of pairwise meta-analysis. Each value and interval refer to the efficacy of the top-row treatment compared to the left column. The order of antidiabetic treatments in this league table is presented in reverse order of the mean rank results. TZD, thiazolidinedione; SGLT2i, sodium-glucose cotransporter-2 inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist; DPP4i, dipeptidyl peptidase-4 inhibitor; Met, metformin; SU, sulfonylurea. [a]Results indicate statistical significance.

(*Continued to the next page*)

Supplementary Fig. 3. Continued

C

	Placebo	DPP4i	GLP-1RA	SU	Met+ TZD	TZD	Met+ SU	Met	SGLT2i	Met+ SGLT2i	Met+ GLP-1RA	DPP4i+ SGLT2i	DPP4i+ TZD	Met+ DPP4i
Placebo	Placebo	−19.5[a] (−33.5 to −5.5)	−37.5[a] (−54.1 to −21.1)	−25.4[a] (−45.2 to −5.7)	−27.6[a] (−45.0 to −10.2)	−30.6[a] (−48.5 to −12.6)	−31.6 (−64.7 to 1.5)	−13.0[a] (−25.4 to −0.7)	−36.9[a] (−54.8 to −19.1)	−40.6[a] (−67.1 to −14.1)	−41.6[a] (−58.5 to −24.6)	−42.5[a] (−60.4 to −24.7)	−45.2[a] (−63.8 to −26.7)	−48.0[a] (−71.7 to −24.4)
DPP4i	10.7[a] (9.8 to 11.6) I^2=68.6% 16 sutides	DPP4i	−18.1[a] (−33.4 to −2.7)	−5.9 (−24.7 to 12.8)	−8.1 (−24.4 to 8.2)	−11.0 (−27.9 to 5.8)	−12.1 (−44.7 to 20.5)	−4.9 (−15.6 to 5.7)	−17.4[a] (−28.5 to −6.4)	−21.1 (−46.9 to 4.7)	−22.0[a] (−37.9 to −6.2)	−23.0[a] (−34.1 to −12.0)	−25.7[a] (−38.0 to −13.5)	−28.5[a] (−51.3 to −5.7)
GLP-1RA	23.9[a] (20.7 to 27.1) I^2=71.9% 4 studies		GLP-1RA	12.1 (−4.7 to 29.0)	10.0 (−4.1 to 24.0)	7.0 (−7.7 to 21.7)	6.0 (−25.6 to 37.5)	8.4 (−10.4 to 27.2)	0.6 (−18.3 to 19.5)	−3.0 (−27.5 to 21.4)	−4.0 (−17.6 to 9.6)	−5.0 (−23.9 to 13.9)	−7.7 (−27.3 to 11.9)	−10.5 (−31.8 to 10.9)
SU	6.4 (−2.6 to 15.4) I^2=89.6% 2 studies	−2.5 (−15.6 to 10.6) I^2=0.0% 1 study	−10.7[a] (−15.2 to −6.3) I^2=0.0% 1 study	SU	−2.2 (−19.9 to 15.5)	−5.1 (−23.3 to 13.1)	−6.2 (−39.5 to 27.1)	−14.2 (−31.7 to 3.4)	−11.5 (−33.3 to 10.3)	−15.2 (−41.9 to 11.5)	−16.1 (−33.4 to 1.2)	−17.1 (−38.9 to 4.7)	−19.8 (−42.2 to 2.6)	−22.6 (−46.5 to 1.3)
Met+ TZD					Met+ TZD	−2.9 (−18.6 to 12.8)	−4.0 (−36.0 to 28.0)	8.1 (−14.6 to 30.7)	−9.3 (−29.0 to 10.4)	−13.0 (−38.0 to 12.0)	−13.9 (−28.5 to 0.7)	−14.9 (−34.6 to 4.8)	−17.6 (−38.0 to 2.8)	−20.4 (−42.4 to 1.6)
TZD	12.6[a] (3.9 to 21.4) I^2=48.5% 2 studies	21.9[a] (14.0 to 29.8) I^2=0.0% 1 study		−0.2 (−1.7 to 1.3) I^2=0.0% 4 studies	−9.0[a] (−15.6 to −2.5) I^2=0.0% 1 study	TZD	−1.0 (−33.3 to 31.2)	12.7 (−4.7 to 30.0)	−6.4 (−26.5 to 13.8)	−10.0 (−35.4 to 15.4)	−11.0 (−26.2 to 4.2)	−12.0 (−32.1 to 8.2)	−14.7 (−35.5 to 6.1)	−17.5 (−40.0 to 5.0)
Met+ SU							Met+ SU	11.9 (−3.7 to 27.6)	−5.3 (−39.7 to 29.1)	−9.0 (−29.0 to 10.9)	−10.0 (−41.7 to 21.8)	−10.9 (−45.3 to 23.5)	−13.6 (−48.4 to 21.2)	−16.4 (−39.7 to 6.9)
Met	14.1[a] (9.7 to 18.4) I^2=81.4% 5 sutides	8.6[a] (5.9 to 11.3) I^2=0.0% 5 studies	4.0 (−0.6 to 8.6) I^2=0.0% 2 studies	−1.1 (−2.6 to 0.4) I^2=0.0% 5 studies	−1.9 (−7.0 to 3.1) I^2=60.8% 3 studies	−0.9 (−2.4 to 0.5) I^2=35.2% 7 studies		Met	−10.0 (−26.5 to 6.6)	−9.0 (−19.0 to 1.0)	−15.5 (−34.7 to 3.8)	1.0 (−29.2 to 31.1)	−4.4 (−18.7 to 9.9)	−2.6 (−25.5 to 20.4)
SGLT2i	32.2[a] (28.8 to 35.5) I^2=46.1% 6 studies	16.2[a] (12.2 to 20.2) I^2=0.0% 2 studies							SGLT2i	−3.7 (−31.7 to 24.4)	−4.6 (−23.9 to 14.7)	−5.6 (−16.1 to 4.9)	−8.3 (−24.8 to 8.2)	−11.1 (−36.5 to 14.3)
Met+ SGLT2i							9.0 (−8.7 to 26.7) I^2=0.0% 1 study			Met+ SGLT2i	−1.0 (−25.7 to 23.8)	−1.9 (−30.0 to 26.1)	−4.6 (−33.2 to 23.9)	−7.4 (−19.5 to 4.7)
Met+ GLP-1RA								9.0[a] (5.4 to 12.6) I^2=0.0% 1 study			Met+ GLP-1RA	−1.0 (−20.3 to 18.3)	−3.7 (−23.7 to 16.3)	−6.5 (−28.1 to 15.2)
DPP4i+ SGLT2i		23.0[a] (17.0 to 29.0) I^2=0.0% 1 study							5.6[a] (0.7 to 10.5) I^2=0.0% 1 study			DPP4i+ SGLT2i	−2.7 (−19.2 to 13.8)	−5.5 (−30.9 to 19.9)
DPP4i+ TZD		25.7[a] (17.8 to 33.7) I^2=0.0% 1 study				3.8 (−1.9 to 9.5) I^2=0.0% 1 study							DPP4i+ TZD	−2.8 (−28.7 to 23.1)
Met+ DPP4i	51.3[a] (40.7 to 61.9) I^2=0.0% 1 study	31.5[a] (22.9 to 40.1) I^2=0.0% 1 study						16.8[a] (9.2 to 24.5) I^2=0.0% 2 studies		7.4 (−0.4 to 15.1) I^2=0.0% 1 study				Met+ DPP4i